KR102189891B1 - Composition for preventing or treating andropause related symptoms comprising the extract of rice bran - Google Patents
Composition for preventing or treating andropause related symptoms comprising the extract of rice bran Download PDFInfo
- Publication number
- KR102189891B1 KR102189891B1 KR1020190001336A KR20190001336A KR102189891B1 KR 102189891 B1 KR102189891 B1 KR 102189891B1 KR 1020190001336 A KR1020190001336 A KR 1020190001336A KR 20190001336 A KR20190001336 A KR 20190001336A KR 102189891 B1 KR102189891 B1 KR 102189891B1
- Authority
- KR
- South Korea
- Prior art keywords
- rice bran
- extract
- male
- composition
- preventing
- Prior art date
Links
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 93
- 235000009566 rice Nutrition 0.000 title claims abstract description 93
- 239000000284 extract Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 208000024891 symptom Diseases 0.000 title description 3
- 240000007594 Oryza sativa Species 0.000 title 1
- 241000209094 Oryza Species 0.000 claims abstract description 92
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 62
- 206010027304 Menopausal symptoms Diseases 0.000 claims abstract description 33
- 229960003604 testosterone Drugs 0.000 claims abstract description 31
- 235000013305 food Nutrition 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 230000007423 decrease Effects 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 26
- 229940088597 hormone Drugs 0.000 abstract description 24
- 239000005556 hormone Substances 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 16
- 230000028327 secretion Effects 0.000 abstract description 16
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 230000002381 testicular Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 3
- 230000001548 androgenic effect Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 230000032683 aging Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 210000001550 testis Anatomy 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 101150017665 CYP11A1 gene Proteins 0.000 description 7
- 101150051357 CYP17A1 gene Proteins 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- -1 fluoroalkane Chemical compound 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 102000000827 Anterior Pituitary Hormones Human genes 0.000 description 2
- 108010001897 Anterior Pituitary Hormones Proteins 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010051482 Prostatomegaly Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003329 adenohypophysis hormone Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000003592 new natural product Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 쌀겨 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 남성 고환 세포에서 남성호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론의 분비 촉진 효과를 나타내는 쌀겨 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물에 관한 것이다.
본 발명이 제공하는 쌀겨 추출물은 남성 호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론 분비 촉진 효과를 나타내어 남성 갱년기 증후군 치료제 또는 개선용 식품 개발에 매우 유용하게 활용이 될 수 있다.The present invention relates to a composition for preventing or treating male menopausal syndrome comprising a rice bran extract, and more particularly, to a composition for preventing or treating male menopausal syndrome, and more particularly, it includes a rice bran extract that increases the expression of androgenic genes and proteins in male testicular cells and promotes the secretion of testosterone. It relates to a composition for preventing or treating male menopausal syndrome.
The rice bran extract provided by the present invention increases the expression of male hormone-related genes and proteins, and exhibits an effect of promoting testosterone secretion, and thus can be very usefully used in the development of foods for treating or improving male menopausal syndrome.
Description
본 발명은 쌀겨 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 남성 고환 세포에서 남성호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론의 분비 촉진 효과를 나타내는 쌀겨 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing or treating male menopausal syndrome comprising a rice bran extract, and more particularly, to a composition for preventing or treating male menopausal syndrome, and more particularly, it includes a rice bran extract that increases the expression of androgenic genes and proteins in male testicular cells and promotes the secretion of testosterone. It relates to a composition for preventing or treating male menopausal syndrome.
우리나라 65세 이상 노인 인구는 2000년도에 이미 7%을 돌파하여 노령화 사회에 진입하게 되었고 현재 14%을 넘어서서 본격적인 노령사회가 시작되고 있다. 문제는 노령화 사회에서 노령사회로 넘어가는 기간이 기존의 선진 국가들이 80년에서 100년이 소요되었던 것에 비해 우리나라는 20년도 채 되지 않아 너무 급격하게 노인인구가 증가하게 된다는 사실이다. 노령사회가 되면 사회 정책적인 면에서도 많은 변화가 있겠지만 의료면에서도 많은 변화를 예측할 수가 있다. 비뇨기과적으로는 전립선 비대증이나 전립선암과 성기능장애 및 남성갱년기 증상 같은 남성호르몬이 관련된 질환들이 증가할 것으로 보인다.The number of elderly people aged 65 or older in Korea exceeded 7% in 2000 and entered an aging society, and now exceeding 14%, an aging society is starting in earnest. The problem is that the transition from an aging society to an aging society takes less than 20 years in Korea compared to 80 to 100 years in existing advanced countries, and the elderly population increases too rapidly. In an aging society, there will be many changes in terms of social policy, but many changes can be predicted in terms of medical care. Urologically, male hormone-related diseases such as enlarged prostate, prostate cancer, sexual dysfunction, and menopausal symptoms are expected to increase.
여성은 여성호르몬이 월중변화를 보이다가 50대 초반에 폐경이 되면서 완전히 바닥으로 내려오지만 남성에서는 여성과는 달리 나이가 들면서 서서히 감소하기 때문에 노인이 되더라도 일정 수준의 호르몬은 계속 분비가 되기 때문에 여성에서처럼 갱년기 증상이 뚜렷하거나 또한 모든 사람에서 나타나는 것은 아니다. 그래서 남성갱년기를 male climacteric, andropause외에도 PADAM(partial androgen deficiency in aging male)으로도 부르고 있다.In women, female hormones change throughout the month and then come to the bottom of menopause in the early 50s, but unlike women, in men, they gradually decrease with age, so a certain level of hormones continue to be secreted even in the elderly. Menopausal symptoms are obvious or not in everyone. So, in addition to male climacteric and andropause, male menopause is also called PADAM (partial androgen deficiency in aging male).
노화와 관련된 테스토스테론(testosterone) 저하는 그 시작연령, 진행속도, 저하정도의 개인차가 큰 편이다. 대체로 50세 이후 혈중 테스토스테론 치는 1년에 1% 정도 감소한다. 이 같은 감소는 60세 이전에는 7%에서만 발견되지만 60세 이후에는 20% 정도로 증가한다. 그러나 노화에 따른 SHBG의 증가로 bioavailable 테스토스테론은 더욱 감소하므로 실제 PADAM의 빈도는 이보다 더 흔할 것으로 추정된다. 노화에 따른 또 다른 변화는 남성호르몬의 일중 변동이 없어져서 24시간 내내 낮은 농도를 유지한다는 것이다. The decrease in testosterone related to aging tends to have a large individual difference in the starting age, progression speed, and degree of decline. In general, blood testosterone levels decrease by 1% per year after
그런데 남성갱년기 증상은 테스토스테론의 감소로 인해서만 나타나는 것은 아니다. 과거에는 남성호르몬의 결핍만이 그 원인인 것으로 생각하였던 증상의 상당부분이 다른 호르몬의 변화에 기인함이 밝혀지고 있다. 성장호르몬은 사춘기 이후에 매 10년마다 약 14% 정도씩 생산이 감소하고 있다. 성장 호르몬에 의해 생산이 조절되는 IGF-1 (insulin-like growth factor-1)도 함께 감소한다. 저 혈당과 암 시야에 반응해 송과선(pineal gland)에 서 분비되는 멜라토닌도 노화에 따라 감소한다. However, menopausal symptoms are not only caused by a decrease in testosterone. In the past, it has been found that many of the symptoms that were thought only to be the cause of male hormone deficiency are due to changes in other hormones. Growth hormone production is decreasing by about 14% every 10 years after puberty. Insulin-like growth factor-1 (IGF-1), which is regulated by growth hormone production, also decreases. Melatonin released from the pineal gland in response to hypoglycemia and dark vision also decreases with aging.
테스토스테론을 비롯하여 다양한 호르몬의 저하에 따라 성적 욕구감소, 발기능력의 저하, 우울함과 짜증을 수반하는 기분의 저하, 기억력 감소, 제지방량의 감소, 체모의 감소와 피부노화, 골밀도 감소, 내장지방 증가 등이 나타난다고 한다(대한 성학회. 제1회 의사를 위한 성치료 교육과정 2003. 11.). 이러한 남성 갱년기의 원인은 기타 환경적 요인 외에도 내분비계의 쇠태에 있어 그 동안은 남성 호르몬의 보충치료가 주된 치료요법으로 알려져 왔다. 남성 호르몬 보충요법은 먹는 약이나 바르는 제제, 붙이는 패치형 제제, 주사요법 등이 있다.Decreased sexual desire, decreased erectile ability, decreased mood accompanying depression and irritability, decreased memory, decreased lean mass, decreased body hair and skin aging, decreased bone density, increased visceral fat, etc. due to decreases in various hormones including testosterone (Korean Sexual Association. The 1st Sexual Therapy Curriculum for Doctors 2003. 11.). In addition to other environmental factors, the cause of this male menopause is the decline of the endocrine system. Until now, male hormone supplementation therapy has been known as the main therapy. Male hormone supplementation therapy includes medicines to be eaten or applied, patch-type preparations to be applied, and injection therapy.
그러나, 남성 호르몬 요법을 통한 남성 갱년기 증상의 치료는 전립선의 크기를 증가시켜 이미 발생한 전립선암 크기를 증가시키거나 수면 중 무호흡증의 악화, 여성형 유방 발생, 적혈구증가증 발생, 심혈관질환 위험도 증가 등의 부작용이 따를 수 있다. 또한, 이러한 호르몬 치료요법은 남성 갱년기 증상의 근본적인 발병 원인을 치료하지는 못하며, 남자라면 누구나 나이가 들면서 남성 갱년기 증세를 겪게 되므로 그 예방이 무엇보다 중요하다. 따라서, 이러한 부작용이 없이 증상의 진행과정을 막아줄 수 있는 예방제 및 치료제의 개발이 절실히 요구되는 실정이다.However, treatment of male menopausal symptoms through male hormone therapy increases the size of the prostate, leading to an increase in the size of prostate cancer that has already occurred, or worsening apnea during sleep, gynecomastia, erythropoiesis, and cardiovascular disease risk. You can follow. In addition, such hormonal therapy cannot cure the underlying cause of male menopausal symptoms, and any man will experience male menopausal symptoms as he ages, so its prevention is of paramount importance. Therefore, there is an urgent need to develop a preventive agent and a therapeutic agent capable of preventing the progression of symptoms without such side effects.
한편, 쌀겨(미강) 추출물의 주요 구성성분인 감마-오리자놀(gamma-oryzanol)은 GABA 성분과 유사한 작용으로 자율신경을 안정화시키며, 여성 갱년기 때 증가하는 뇌하수체 전엽 호르몬 (LH, TSH, GH, PRL)의 분비를 억제하는 효과로 인해 여성의 폐경 증후군 완화에 효과를 나타내는 것으로 보고되고 있다. On the other hand, gamma-oryzanol, a major component of rice bran (rice bran) extract, stabilizes the autonomic nervous system through an action similar to that of GABA, and anterior pituitary hormones (LH, TSH, GH, PRL) that increase during female menopause. It has been reported to be effective in relieving menopause syndrome in women due to the effect of inhibiting the secretion of
하지만, 감마 오리자놀 보충제를 투여 받은 성인 남성에서 혈중 테스토스테론의 분비량이 증가하지 않았다는 것을 보고하고 있는 문헌이 있을 뿐만 아니라(Int J Sport Nutr. 1997 Dec;7(4): 318-29), 쌀겨 추출물이 남성 갱년기 증후군에 효과를 나타낸다는 것을 보고하고 있는 문헌은 전무한 실정이다.However, not only literature reports that blood testosterone levels did not increase in adult males receiving gamma-orizanol supplementation (Int J Sport Nutr. 1997 Dec; 7(4): 318-29), as well as rice bran extract. There is no literature reporting that it has an effect on male menopausal syndrome.
이에, 본 발명자는 남성 갱년기 증후군 개선 효능이 뛰어난 새로운 천연물 유래의 소재를 개발하고자 예의 연구를 거듭한 결과, 쌀겨 추출물이 남성 호르몬 관련 유전자의 발현을 증가시키고 테스토스테론의 분비량을 증가시켜 남성 갱년기 증후군의 예방 또는 치료 소재로서 활용이 될 수 있음을 발견하고 본 발명을 완성하였다. Accordingly, the inventors of the present invention conducted extensive research to develop a new natural product-derived material with excellent efficacy in improving male menopausal syndrome. As a result, rice bran extract increased the expression of male hormone-related genes and increased the secretion of testosterone to prevent male menopausal syndrome. Alternatively, it was found that it could be utilized as a therapeutic material and the present invention was completed.
따라서, 본 발명의 목적은 쌀겨 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 치료용 약학적 조성물을 제공하는 것이다. Accordingly, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating male menopausal syndrome comprising rice bran extract as an active ingredient.
본 발명의 다른 목적은 쌀겨 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a food composition for preventing or improving male menopausal syndrome comprising a rice bran extract as an active ingredient.
상기한 본 발명의 목적을 달성하기 위하여 본 발명은 쌀겨 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 치료용 약학적 조성물을 제공한다. In order to achieve the above object of the present invention, the present invention provides a pharmaceutical composition for preventing or treating male menopausal syndrome comprising rice bran extract as an active ingredient.
본 발명의 다른 목적을 달성하기 위하여 본 발명은 쌀겨 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 제공한다. In order to achieve another object of the present invention, the present invention provides a food composition for preventing or improving male menopausal syndrome comprising rice bran extract as an active ingredient.
이하, 본 발명에 대하여 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 쌀겨 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 치료용 약학적 조성물을 제공한다. The present invention provides a pharmaceutical composition for preventing or treating male menopausal syndrome comprising rice bran extract as an active ingredient.
쌀겨(미강)는 쌀 영양분의 약 95%가 집결되어 있으며, 양질의 단백질과 식이섬유 및 각종 비타민과 미네랄이 함유되어 있다. 쌀겨의 효능으로는 항암, 항산화, 항염증, 항동맥경화, 콜레스테롤 저하, 성장촉진작용, 소화기능 촉진 및 면역강화 작용 등이 밝혀졌다. Rice bran (rice bran) contains about 95% of rice nutrients and contains high-quality protein, dietary fiber, and various vitamins and minerals. The efficacy of rice bran has been found to have anti-cancer, anti-oxidation, anti-inflammatory, anti-arteriosclerosis, cholesterol lowering, growth promotion, digestive function promotion, and immunity strengthening.
또한, 쌀겨의 주요 구성성분인 감마-오리자놀은 GABA 성분과 유사한 작용으로 자율신경을 안정화시키며, 여성 갱년기 때 증가하는 뇌하수체 전엽 호르몬 (LH, TSH, GH, PRL)의 분비를 억제하는 효과로 인해 여성의 폐경 증후군 완화에 효과를 나타내는 것으로 보고되고 있다. In addition, gamma-orizanol, a major constituent of rice bran, stabilizes the autonomic nervous system through a similar action to GABA, and inhibits the secretion of anterior pituitary hormones (LH, TSH, GH, PRL), which increases during women's menopause. It has been reported to be effective in relieving menopausal syndrome.
하지만, 쌀겨 추출물과 남성 갱년기 증후군, 보다 구체적으로는 테스토스테론 감소증의 상관관계에 대해서는 아직까지 보고된 바가 없다. However, the correlation between rice bran extract and male menopausal syndrome, more specifically testosterone reduction, has not been reported yet.
한편, 쌀겨의 주요 구성성분인 감마-오리자놀은 물에 의해서는 거의 추출이 되지 않으며, 에탄올에 의해서는 추출 수율이 우수한 것으로 확인된 바 있고(한국 공개특허공보 제10-2012-0117539), 감마 오리자놀 보충제를 투여 받은 성인 남성에서 혈중 테스토스테론의 분비량이 증가하지 않았다는 것이 보고된 바 있다(Int J Sport Nutr. 1997 Dec;7(4): 318-29). On the other hand, gamma-orizanol, a major constituent of rice bran, is hardly extracted by water, and it has been confirmed that the extraction yield is excellent by ethanol (Korean Laid-Open Patent Publication No. 10-2012-0117539), and gamma-orizanol It has been reported that there is no increase in blood testosterone secretion in adult males receiving supplementation (Int J Sport Nutr. 1997 Dec;7(4):318-29).
그런데, 본 발명의 일실시예에 따르면 쌀겨 가루의 열수 추출물과 주정 추출물은 모두 남성 고환 세포주에서 남성 호르몬 관련 유전자 및 단백질의 발현을 증가시켰고, 실제로 테스토스테론의 분비량 또한 증가시키는 것이 확인 되었다. 이러한 본 발명의 일실시예 및 종래 기술을 참고하면, 쌀겨 가루 추출물의 남성 호르몬 분비 촉진 효과는 감마-오리자놀에 의한 것이 아닌 다른 구성성분들에 의한 효과인 것으로 판단해 볼 수 있다.By the way, according to an embodiment of the present invention, both the hot water extract and the alcohol extract of rice bran powder increased the expression of male hormone-related genes and proteins in male testicular cell lines, and it was confirmed that the secretion of testosterone also increased. Referring to such an embodiment of the present invention and the prior art, the effect of promoting male hormone secretion of the rice bran powder extract may be judged to be an effect not caused by gamma-orizanol but by other components.
본 발명에서 상기 쌀겨 추출물은 광의로는 쌀겨 자체를 동물에게 투여할 수 있도록 제형화된 쌀겨 가공물, 예컨대, 쌀겨 가루도 포함하는 의미를 갖는다. 비록 본 발명에서 쌀겨 가루 추출물로 실험을 진행하긴 하였으나, 쌀겨 자체와 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상 가능할 것이다.In the present invention, the rice bran extract has a meaning to include a processed rice bran, such as rice bran powder, formulated to administer the rice bran itself to an animal in a broad sense. Although the experiment was conducted with the rice bran powder extract in the present invention, it will be expected by those skilled in the art that the desired effect can be achieved even in the same form as the rice bran itself.
본 발명에 있어서, 상기 쌀겨 추출물은 쌀겨의 물, 유기용매 또는 이들의 혼합물을 추출 용매로서 이용하여 추출된 것일 수 있다. 이 때 사용되는 유기용매의 종류나 물과 유기용매의 혼합 비율은 특별히 제한되지 않는다. In the present invention, the rice bran extract may be extracted using water, an organic solvent, or a mixture thereof of rice bran as an extraction solvent. At this time, the type of organic solvent used or the mixing ratio of water and organic solvent is not particularly limited.
예를 들어, 상기 유기용매는 저급 알코올, 헥산, 아세톤, 에틸 아세테이트, 클로로포름, 및 디에틸에테르로 이루어진 군으로부터 선택된 하나 이상의 용매일 수 있다. 상기 저급 알코올은 탄소수 1 내지 6의 알코올일 수 있다. 예를 들어, 저급 알코올로는 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜 등을 이용할 수 있다. 유기용매는 이 외에도 아세트산, DMFO(dimethyl-formamide), DMSO(dimethyl sulfoxide) 등의 극성 용매, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 2,2,4-트리메틸펜탄, 데칸, 사이클로헥산, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소 및 THF(Tetrahydrofuran) 등의 비극성 용매를 사용할 수도 있다. 바람직하게는, 본 발명에서 상기 쌀겨 추출물은 극성 용매에 의한 추출물일 수 있으며, 더 바람직하게는 물 또는 탄소수 1 내지 6개의 알코올 추출물일 수 있으며, 가장 바람직하게는 물 추출물일 수 있다. For example, the organic solvent may be one or more solvents selected from the group consisting of lower alcohol, hexane, acetone, ethyl acetate, chloroform, and diethyl ether. The lower alcohol may be an alcohol having 1 to 6 carbon atoms. For example, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol, or ethylene glycol may be used as the lower alcohol. In addition to organic solvents, polar solvents such as acetic acid, dimethyl-formamide (DMFO), and dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, decane , Cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene , Benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and non-polar solvents such as THF (Tetrahydrofuran) may be used. Preferably, in the present invention, the rice bran extract may be an extract using a polar solvent, more preferably water or an alcohol extract having 1 to 6 carbon atoms, and most preferably a water extract.
본 발명 추출물은 공지의 천연물 추출법으로 추출될 수 있다. 예를 들어 냉침추출, 열수추출, 용매추출, 초음파 추출, 환류냉각 추출, 가열 추출법으로 추출할 수 있으며, 바람직하게는 열수추출, 용매추출 또는 환류 냉각 추출법으로 추출할 수 있으며, 더 바람직하게는 열수추출 또는 용매추출일 수 있으며, 가장 바람직하게는 열수추출일 수 있다. 또한, 상기 추출은 1회 내지 10회, 바람직하게는 2회 내지 7회 반복 추출할 수 있다.The extract of the present invention may be extracted by a known natural product extraction method. For example, it can be extracted by cold needle extraction, hot water extraction, solvent extraction, ultrasonic extraction, reflux cooling extraction, heat extraction method, preferably hot water extraction, solvent extraction or reflux cooling extraction method, more preferably hot water It may be extraction or solvent extraction, and most preferably hot water extraction. In addition, the extraction may be repeated 1 to 10 times, preferably 2 to 7 times.
쌀겨를 유기용매로 추출할 경우 쌀겨 추출물은 상층액과 하층액으로 분리되는데, 상층액은 쌀겨 추출물의 오일 분획이며, 하층액은 일반적인 용매 추출물에 해당한다. 하층액을 다시 원심분리 또는 여과지를 통해 분리하면 액상과 고형 상태의 잔사로 나눠지는데 이 때의 잔사는 쌀겨 추출물의 왁스 분획이다. 따라서, 본 발명의 쌀겨 추출물은 쌀겨 추출물의 오일 분획, 쌀겨 추출물의 액상 분획, 쌀겨 추출물의 왁스 분획을 모두 포함하는 개념으로 해석된다. 즉, 상기 쌀겨 추출물은 쌀겨 추출물의 오일 분획, 쌀겨 추출물의 액상 분획 및 쌀겨 추출물의 왁스 분획으로 이루어진 군으로부터 선택된 어느 하나 이상을 포함할 수 있다.When the rice bran is extracted with an organic solvent, the rice bran extract is separated into a supernatant and a lower liquid, and the supernatant is the oil fraction of the rice bran extract, and the lower liquid corresponds to a general solvent extract. When the lower layer is separated again by centrifugation or filter paper, it is divided into liquid and solid residues, and the residue at this time is the wax fraction of rice bran extract. Accordingly, the rice bran extract of the present invention is interpreted as a concept including all of the oil fraction of the rice bran extract, the liquid fraction of the rice bran extract, and the wax fraction of the rice bran extract. That is, the rice bran extract may include any one or more selected from the group consisting of an oil fraction of rice bran extract, a liquid fraction of rice bran extract, and a wax fraction of rice bran extract.
본 명세서에서 쌀겨를 언급하면서 사용되는 용어 '추출물'은 쌀겨에 추출용매를 처리하여 얻은 조추출물 뿐만 아니라 쌀겨 추출물의 가공물도 포함한다. 예를 들어, 쌀겨 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The term'extract' used in referring to rice bran in this specification includes not only the crude extract obtained by treating the rice bran with an extraction solvent, but also the processed product of the rice bran extract. For example, the rice bran extract may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
본 발명에서 상기 남성 갱년기 증후군이란 신체 노화에 따라 남성에게서 발생하는 다양한 생리학적 현상을 의미하는 것으로서 이는 남성 호르몬, 성장 호르몬 등 다양한 호르몬의 분비 감소에 의한 내인적인 요인과 고립감, 소외감, 박탈감 등 개인을 둘러싼 다양한 환경적인 영향에 따른 심리적인 요인들이 복합적으로 작용하여 나타나게 된다. 상기 갱년기 증후군은 이에 제한되는 것은 아니나, 성선기능저하증, 전립선 비대증, 하부요로증상, 신경과민, 정서불안, 우울증, 안면홍조, 수면장애, 활력저하, 업무능력감소, 성욕감퇴, 발기부전, 정력감소, 체력저하, 운동능력감소, 체모감소 및 테스토스테론 저하증으로 이루어진 군에서 선택될 수 있으며, 바람직하게는 테스토스테론 저하증일 수 있다. In the present invention, the male menopausal syndrome refers to various physiological phenomena that occur in men according to body aging, which is an endogenous factor due to the decrease in secretion of various hormones such as male hormones and growth hormones, and a feeling of isolation, alienation, and deprivation. Psychological factors according to the various environmental influences that surround it appear as a complex action. The menopausal syndrome is not limited thereto, but hypogonadism, enlarged prostate, lower urinary tract symptoms, nervousness, emotional anxiety, depression, facial flushing, sleep disorders, decreased vitality, decreased work capacity, decreased libido, erectile dysfunction, decreased energy , It may be selected from the group consisting of decrease in physical strength, decrease in exercise capacity, decrease in body hair, and decrease in testosterone, and preferably may be low testosterone.
한편, 본 명세서에서 용어 '유효성분으로 포함하는'이란 쌀겨 추출물 또는 쌀겨 분말의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명의 한 구체예에서, 본 발명의 조성물 내에서 쌀겨 추출물 또는 쌀겨 분말은 예를 들어, 0.001 mg/kg 이상, 바람직하게는 0.1 mg/kg 이상, 보다 바람직하게는 10 mg/kg 이상, 보다 더 바람직하게는 100 mg/kg 이상, 보다 더욱 더 바람직하게는 250 mg/kg 이상, 가장 바람직하게는 0.1 g/kg 이상 포함된다. 쌀겨 추출물 또는 쌀겨 분말은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 쌀겨 추출물 또는 쌀겨 분말의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.Meanwhile, in the present specification, the term'including as an active ingredient' means including an amount sufficient to achieve the efficacy or activity of the rice bran extract or rice bran powder. In one embodiment of the present invention, the rice bran extract or rice bran powder in the composition of the present invention is, for example, 0.001 mg/kg or more, preferably 0.1 mg/kg or more, more preferably 10 mg/kg or more, more More preferably 100 mg/kg or more, even more preferably 250 mg/kg or more, and most preferably 0.1 g/kg or more. Since the rice bran extract or rice bran powder is a natural product and does not have side effects on the human body even if it is administered in an excessive amount, the upper limit of the quantity of the rice bran extract or rice bran powder included in the composition of the present invention can be selected and carried out within an appropriate range by a person skilled in the art.
본 발명의 약학적 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant includes excipients, disintegrants, sweetening agents, binders, coating agents, expanding agents, lubricants, It is possible to use a lubricant or flavoring agent.
상기 약학적 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다. The pharmaceutical composition may be preferably formulated as a pharmaceutical composition, including at least one pharmaceutically acceptable carrier in addition to the above-described active ingredient for administration.
상기 약학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다. The formulation form of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops, or injectable solutions. For example, for formulation in the form of tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, lacquercanth or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다. As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injectable formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 성분에 따라 바람직하게 제제화 할 수 있다. Further, it can be preferably formulated according to the ingredients using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc., preferably oral administration. .
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약제학적 조성물의 1일 투여량은 0.001-10g/㎏이다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, Usually, the skilled practitioner can readily determine and prescribe the dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10g/kg.
본 발명의 약학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화 함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in a unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art. Or it can be made by incorporating it into a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.
본 발명은 또한 쌀겨 추출물을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 제공한다. The present invention also provides a food composition for preventing or improving male menopausal syndrome comprising a rice bran extract as an active ingredient.
본 발명에 따른 식품 조성물은 상기 약학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition to be used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectionery, diet bars, dairy products, meat, chocolate, pizza, ramen, other noodles, gum, ice cream, vitamin complexes, health supplements. Etc.
본 발명의 식품 조성물은 유효성분으로서 쌀겨 추출물 또는 쌀겨 분말 뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 쌀겨 추출물 또는 쌀겨 분말 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may include not only rice bran extract or rice bran powder as an active ingredient, but also ingredients commonly added during food production, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. Include. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, in addition to the rice bran extract or rice bran powder of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be additionally included. I can.
본 발명은 상기 쌀겨 추출물 또는 쌀겨 분말을 유효성분으로 포함하는 남성 갱년기 증후군 예방 또는 개선용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 쌀겨 추출물 또는 쌀겨 분말을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 쌀겨 추출물 또는 쌀겨 분말의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food comprising a food composition for preventing or improving male menopausal syndrome comprising the rice bran extract or rice bran powder as an active ingredient. Health functional foods are foods prepared by adding rice bran extract or rice bran powder to food materials such as beverages, teas, spices, chewing gum, confectionery, etc., or prepared by encapsulation, powdering, or suspension. It means to bring it, but unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material. The health functional food of the present invention obtained in this way is very useful because it can be consumed on a daily basis. The amount of rice bran extract or rice bran powder added in such health functional foods cannot be uniformly regulated depending on the type of health functional food, but can be added within the range that does not damage the original taste of the food. It is usually 0.01 to 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of health functional foods in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
본 발명이 제공하는 쌀겨 추출물은 남성 호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론 분비 촉진 효과를 나타내어 남성 갱년기 증후군 치료제 또는 개선용 식품 개발에 매우 유용하게 활용이 될 수 있다. The rice bran extract provided by the present invention increases the expression of male hormone-related genes and proteins, and exhibits an effect of promoting testosterone secretion, and thus can be very usefully used in the development of foods for treating or improving male menopausal syndrome.
도 1은 마우스 고환 세포주 TM3에 쌀겨 가루 열수 추출물을 농도별로 24시간 동안 처리한 후 남성 호르몬 관련 유전자 (StAR, Cyp11a1, Cyp17a1)의 mRNA 발현 변화를 qRT-PCR로 측정한 결과이다.
도 2는 마우스 고환 세포주 TM3에 쌀겨 가루 열수 추출물을 농도별로 24시간 동안 처리한 후 남성 호르몬 관련 단백질 (StAR, Cyp11a1, Cyp17a1)의 발현량 변화를 웨스턴 블롯으로 측정한 결과이다.
도 3은 마우스 고환 세포주 TM3에 쌀겨 가루 주정 추출물을 농도별로 24시간 동안 처리한 후 남성 호르몬 관련 유전자 (StAR, Cyp11a1, Cyp17a1)의 mRNA 발현 변화를 qRT-PCR로 측정한 결과이다.
도 4는 마우스 고환 세포주 TM3에 쌀겨 가루 주정 추출물을 농도별로 24시간 동안 처리한 후 남성 호르몬 관련 단백질 (StAR, Cyp11a1, Cyp17a1)의 발현량 변화를 웨스턴 블롯으로 측정한 결과이다.
도 5는 마우스 고환 세포주 TM3에 쌀겨 가루 열수 추출물을 농도별로 48시간 동안 처리한 후, 세포 배양액 내의 테스토스테론 양을 ELISA로 측정하여 쌀겨 가루 열수 추출물의 테스토스테론 분비 촉진 효과를 확인한 도면이다.
도 6은 마우스 고환 세포주 TM3에 쌀겨 가루 주정 추출물을 농도별로 48시간 동안 처리한 후, 세포 배양액 내의 테스토스테론 양을 ELISA로 측정하여 쌀겨 가루 열수 추출물의 테스토스테론 분비 촉진 효과를 확인한 도면이다.1 is a result of measuring the change in mRNA expression of male hormone-related genes (StAR, Cyp11a1, Cyp17a1) by qRT-PCR after treatment with hot water extract of rice bran powder in mouse testis cell line TM3 for 24 hours by concentration.
Figure 2 is a result of measuring the change in the expression level of male hormone-related proteins (StAR, Cyp11a1, Cyp17a1) by Western blot after treating the hot water extract of rice bran powder to the mouse testis cell line TM3 for 24 hours by concentration.
3 is a result of measuring the change in mRNA expression of male hormone-related genes (StAR, Cyp11a1, Cyp17a1) by qRT-PCR after treating the mouse testis cell line TM3 with rice bran powder alcohol extract for 24 hours by concentration.
4 is a result of measuring the change in the expression level of male hormone-related proteins (StAR, Cyp11a1, Cyp17a1) by Western blot after treating the mouse testis cell line TM3 with rice bran powder alcohol extract for 24 hours by concentration.
Figure 5 is a view confirming the testosterone secretion promoting effect of the rice bran powder hot water extract by measuring the amount of testosterone in the cell culture medium by ELISA after treating the mouse testis cell line TM3 with the hot water extract of rice bran powder by concentration for 48 hours.
6 is a view confirming the testosterone secretion promoting effect of the rice bran powder hot water extract by measuring the amount of testosterone in the cell culture medium by ELISA after treating the mouse testis cell line TM3 with rice bran powder alcohol extract for 48 hours by concentration.
이하, 본 발명을 하기 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명이 이들에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are for illustrative purposes only, and the present invention is not limited thereto.
실시예 1: 실험의 준비Example 1: Preparation of the experiment
마우스 고환 세포주인 TM3 세포 (mouse leydig cell, ATCC® CRL-1714™, mouse testis)를 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 5%, fetal bovine serum 2.5% 에서 37℃, 5% CO2, 95% O2 조건으로 배양하였다. A 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's Medium,
쌀겨 열수 추출물을 제조하기 위해서 수확한 쌀겨를 자연 건조하여 수분이 30~40% 일 때 분쇄기로 분쇄한 후, 분말 30g에 증류수를 고형분 대비 20배 첨가하여 열수추출물 (HE, heat water extraction)을 제조하였다. 열수추출물은 각각 100℃ 및 80℃에서 3시간 동안 환류냉각추출기를 이용하여 추출하였다. 추출물은 불순물울 제거하기 위하여 여과지를 이용하여 여과시켰다. 여과된 용액은 감압농축기를 사용하여 강압농축한 뒤, 동결건조기로 건조하여 분석용 시료로 사용하였다. To prepare the rice bran hot water extract, the harvested rice bran is naturally dried and pulverized with a grinder when the moisture is 30 to 40%, and then distilled water is added 20 times the solid content to 30 g of the powder to prepare a heat water extraction (HE). I did. The hot water extract was extracted using a reflux cooling extractor at 100° C. and 80° C. for 3 hours, respectively. The extract was filtered using a filter paper to remove impurities. The filtered solution was concentrated under reduced pressure using a vacuum concentrator, dried with a freeze dryer, and used as a sample for analysis.
쌀겨 주정 추출물을 제조하기 위해서 수확한 쌀겨를 자연 건조하여 수분이 30~40% 일 때 분쇄기로 분쇄한 후, 분말 30g에 50% 에탄올(EE, 50% ethanol extraction)을 고형분 대비 20배 첨가하여 제조하였다. 주정추출물은 각각 100℃ 및 80℃에서 3시간 동안 환류냉각추출기를 이용하여 추출하였다. 추출물은 불순물울 제거하기 위하여 여과지를 이용하여 여과시켰다. 여과된 용액은 감압농축기를 사용하여 강압농축한 뒤, 동결건조기로 건조하여 분석용 시료로 사용하였다. To prepare rice bran alcohol extract, harvested rice bran is naturally dried and pulverized with a grinder when the moisture is 30-40%, and 50% ethanol (EE, 50% ethanol extraction) is added to 30 g of
상기 TM3 세포에 상기 제조한 쌀겨가루 열수 추출물 분말, 주정 추출물 분말을 각각 멸균한 물 (DDW, distilled deionized water)로 충분히 녹여준다. 각각 0, 1, 10, 25, 50ug/ml의 농도로 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 1%, fetal bovine serum 0.5% 에 녹여서 세포에 처리하였다. The prepared rice bran hot water extract powder and alcohol extract powder are sufficiently dissolved in the TM3 cells with sterilized water (DDW, distilled deionized water), respectively. The cells were treated with a 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's Medium,
실시예 2: 남성호르몬 관련 유전자 및 단백질 발현량 평가Example 2: Evaluation of the expression level of male hormone-related genes and proteins
상기 실시예 1에서 각 추출물 분말을 24시간 처리한 세포에서 mRNA를 추출하였고 (Favogen 회사), Rotor-Gene Q PCR 기계를 (Qiagen 회사)사용하여 qPCR을 실시하였으며, 조건은 95℃, 5분간 denaturation하고, 95℃, 5초간 그리고 60℃, 5초간 40 cycles을 반응시켜서 Cyp11a1, Cyp17a1, StAR 발현량을 측정하였다. 하우스키핑 유전자(House keeping gene)인 18S rRNA를 이용하여 정량화하였다. qPCR에 사용한 프라이머의 서열정보는 하기 표 1에 나타내었다.In Example 1, mRNA was extracted from cells treated with each extract powder for 24 hours (Favogen company), and qPCR was performed using a Rotor-Gene Q PCR machine (Qiagen company), conditions were 95° C., denaturation for 5 minutes. And, 95 ℃, 5 seconds and 60 ℃, by reacting 40 cycles for 5 seconds, Cyp11a1, Cyp17a1, StAR expression levels were measured. It was quantified using 18S rRNA, a house keeping gene. The sequence information of the primers used for qPCR is shown in Table 1 below.
TM3 세포에 쌀겨가루 열수 추출물, 주정 추출물을 멸균한 물 (DDW, distilled deionized water)로 잘 녹인다. 각각 0, 1, 10, 25, 50ug/ml의 농도로 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 1%, fetal bovine serum 0.5% 에 녹여서 48시간동안 처리한 뒤, 세포를 수득하여 통상적인 방법으로 웨스턴 블랏(western blot)실험을 실시하였다.Dissolve the hot water extract of rice bran powder and alcohol extract in TM3 cells with sterilized water (DDW, distilled deionized water). Dissolve in a 1:1 mixture of Ham's F12 medium and Dulbecco's Modified Eagle's Medium,
세포를 용해해서 총단백질을 추출한 다음, SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis)을 통해서 분리하여서, NC (nitrocellulose membrane)에 브랏한 후, 1차 항체(Cyp11a1, Cyp17a1, StAR,β-actin)를 4℃ 에서 12~16 시간 반응한다. TBST (tris-buffered saline tween 20) washing buffer로 충분히 washing 한다. 2차 항체를 실온에서 1시간동안 반응시키고 ECL (enhanced chemiluminescence)로 발색하여 결과를 도출하였다. 각각의 실험군에 대한 Cyp11a1, Cyp17a1, StAR 단백질 발현량을 측정하였다. β-actin을 이용하여 발현량을 정량화 하였다.After lysing the cells to extract the total protein, it was separated through SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) and then brazed on NC (nitrocellulose membrane), and then primary antibodies (Cyp11a1, Cyp17a1, StAR, β-actin) React at 4° C. for 12 to 16 hours. Wash thoroughly with TBST (tris-buffered saline tween 20) washing buffer. The secondary antibody was reacted at room temperature for 1 hour, and the result was obtained by developing color by ECL (enhanced chemiluminescence). The expression levels of Cyp11a1, Cyp17a1, and StAR proteins for each experimental group were measured. The expression level was quantified using β-actin.
이에 대한 결과를 도 1 내지 도 4에 나타내었다. The results are shown in FIGS. 1 to 4.
도 1 및 도 2에 나타낸 바와 같이, 마우스 고환 세포주 TM3에 쌀겨가루 열수 추출물을 처리한 결과, 남성호르몬 관련 유전자 및 단백질의 발현량이 미처리 대조군 대비 현저하게 증가하는 것을 확인할 수 있었다. 특이한 점은, 쌀겨가루 열수 추출물의 이러한 효과는 농도 의존적으로 나타나지는 않았으며, 열수추출물 1 ug/ml 처리군에서 효과가 가장 우수한 것으로 확인이 되었다. As shown in Figures 1 and 2, as a result of treatment with the hot water extract of rice bran powder in the mouse testis cell line TM3, it was confirmed that the expression levels of male hormone-related genes and proteins significantly increased compared to the untreated control group. The peculiar point is that this effect of the hot water extract of rice bran powder did not appear to be concentration dependent, and it was confirmed that the effect was the best in the 1 ug/ml treatment group of the hot water extract.
한편, 도 3 및 도 4에 나타낸 바와 같이, 마우스 고환 세포주 TM3에 쌀겨가루 주정 추출물을 처리한 결과, 열수 추출물과 마찬가지로 남성호르몬 관련 유전자 및 단백질의 발현량이 미처리 대조군 대비 현저하게 증가하였으며, 그 경향성 역시 열수 추출물과 유사하게 1 ug/ml 처리군에서 효과가 가장 우수한 것으로 확인이 되었다. On the other hand, as shown in Figures 3 and 4, as a result of treatment of the rice bran alcohol extract on the mouse testis cell line TM3, the expression level of male hormone-related genes and proteins was significantly increased compared to the untreated control group, like the hot water extract, and the tendency was also Similar to the hot water extract, it was confirmed that the effect was the best in the 1 ug/ml treatment group.
실시예 3: 고환 세포주 TM3에서 테스토스테론의 분비량 평가Example 3: Evaluation of testosterone secretion in testicular cell line TM3
쌀겨가루 (열수 또는 주정 추출물)이 남성 호르몬인 테스토스테론(testosterone) 생성에 미치는 영향을 확인하기 위하여 다음과 같이 실험을 실시하였다. In order to confirm the effect of rice bran powder (hot water or alcohol extract) on the production of testosterone, a male hormone, an experiment was conducted as follows.
TM3 세포에 쌀겨가루 열수 추출물, 주정 추출물을 멸균한 물 (DDW, distilled deionized water)로 잘 녹인 후, 각각 0, 1, 10, 25, 50ug/ml의 농도로 농도로 1:1 mixture of Ham's F12 medium and Dulbecco’s Modified Eagle’s Medium, horse serum 1%, fetal bovine serum 0.5% 에 녹여서 48시간동안 처리한 뒤, testosterone의 양을 측정하고자 세포 배양액 상등액을 수득하여 96 웰 플레이트에 분주하였다. 그 다음 제조사의 지침에 따라 테스토스테론 측정용 ELISA 키트(Testosterone ELISA kit, R&D systems, Cat.# KGE010)를 사용하여, 세포 배양액 내의 테스토스테론의 양(pg/ml)을 측정하였다.After dissolving the hot water extract of rice bran powder and alcohol extract in TM3 cells with sterilized water (DDW, distilled deionized water), 1 mixture of Ham's F12 at a concentration of 0, 1, 10, 25, 50 ug/ml, respectively After dissolving in medium and Dulbecco's Modified Eagle's Medium,
이에 대한 결과를 도 5 및 도 6에 나타내었다. The results are shown in FIGS. 5 and 6.
도 5 및 도 6에 나타낸 바와 같이, 쌀겨가루 열수 추출물과 주정 추출물은 모두 고환 세포주 TM3에서 미처리 대조군 대비 테스토스테론의 분비량을 현저히 증가시키는 것으로 확인이 되었다. As shown in FIGS. 5 and 6, it was confirmed that both the hot water extract of rice bran powder and the alcohol extract significantly increased the amount of testosterone secretion compared to the untreated control group in the testicular cell line TM3.
이상의 결과를 통해, 쌀겨가루 추출물이 테스토스테론 저하에 의한 남성 갱년기 증상에 예방 또는 치료효과를 나타낼 수 있을 것으로 판단해 볼 수 있었다.Through the above results, it could be judged that the rice bran powder extract could exhibit a preventive or therapeutic effect on male menopausal symptoms caused by lower testosterone.
본 발명이 제공하는 쌀겨 추출물은 남성 호르몬 관련 유전자 및 단백질의 발현을 증가시키고 테스토스테론 분비 촉진 효과를 나타내어 남성 갱년기 증후군 치료제 또는 개선용 식품 개발에 매우 유용하게 활용이 될 수 있어 산업상 이용가능성이 매우 우수하다.The rice bran extract provided by the present invention increases the expression of male hormone-related genes and proteins, and exhibits an effect of promoting testosterone secretion, so that it can be very useful in the development of food for the treatment or improvement of male menopausal syndrome, and thus has excellent industrial applicability. Do.
Claims (6)
A pharmaceutical composition for the prevention or treatment of male menopausal syndrome comprising an alcohol extract of water or 1 to 6 carbon atoms of rice bran as an active ingredient.
A food composition for preventing or improving male menopausal syndrome comprising an alcohol extract of water or 1 to 6 carbon atoms of rice bran as an active ingredient.
3. A composition, characterized in that at least one selected from the group consisting of erectile dysfunction, decrease in energy, decrease in physical strength, decrease in exercise capacity, decrease in body hair, and low testosterone.
The composition of claim 1 or 2, wherein the male menopausal syndrome is hypotestosterone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190001336A KR102189891B1 (en) | 2019-01-04 | 2019-01-04 | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190001336A KR102189891B1 (en) | 2019-01-04 | 2019-01-04 | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200085156A KR20200085156A (en) | 2020-07-14 |
| KR102189891B1 true KR102189891B1 (en) | 2020-12-11 |
Family
ID=71526678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190001336A KR102189891B1 (en) | 2019-01-04 | 2019-01-04 | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102189891B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230054121A (en) | 2021-10-15 | 2023-04-24 | 한밭대학교 산학협력단 | Composition for preventing and improving male menopausal syndrome and food composition containing the same |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102231164B1 (en) * | 2019-04-02 | 2021-03-22 | 중앙대학교 산학협력단 | Composition for preventing or treating andropause related symptoms comprising the extract of rice straw |
| KR102563342B1 (en) * | 2021-01-12 | 2023-08-07 | 전북대학교산학협력단 | Method for producing nuroongji extract |
-
2019
- 2019-01-04 KR KR1020190001336A patent/KR102189891B1/en active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| Indian J Med Res, vol.139, pp.857-863 (2014.06.)* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230054121A (en) | 2021-10-15 | 2023-04-24 | 한밭대학교 산학협력단 | Composition for preventing and improving male menopausal syndrome and food composition containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200085156A (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101944985B1 (en) | Composition for differentiating muscle stem cell to muscle cell, pharmaceutical composition for preventing or treating muscle weakness diseases and health functional food composition for enhancing exercise capacity comprising Lithospermum erythrorhizon extract | |
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| US8753694B2 (en) | Anti-angiogenic agents and anti-obesity substances applied with anti-angiogenesis from natural products | |
| KR102189891B1 (en) | Composition for preventing or treating andropause related symptoms comprising the extract of rice bran | |
| JPWO2017159725A1 (en) | Composition for promoting GLP-1 secretion and method for producing the same | |
| KR20220000892A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of barley sprout | |
| KR20210115294A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of wheat sprout | |
| JP2024050702A (en) | Composition containing enterococcus faecalis as active ingredient for preventing or treating obesity or obesity-induced metabolic syndromes | |
| KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR102231164B1 (en) | Composition for preventing or treating andropause related symptoms comprising the extract of rice straw | |
| KR102075836B1 (en) | Composition for preventing or treating menopausal syndrome of women comprising Aristotelia chilensis extract, Angelica sinensis extract and Passiflora incarnata extract as an active ingredient | |
| KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
| KR101732146B1 (en) | Composition for anti-obesity with the extract of corn silk and Poncirus trifoliata | |
| WO2016133155A1 (en) | α-GLUCOSIDASE INHIBITOR | |
| KR20170133820A (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR20210115289A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of licorice | |
| KR20200085158A (en) | Composition for preventing or treating andropause related symptoms comprising the extract of red clover | |
| JP6513404B2 (en) | Fat burning promoter and hypothermia improving agent | |
| KR101811210B1 (en) | Composition for treatment, improvement or prevention of Diabetes comprising extract of fruit of Sorbus commixta as an effective component | |
| KR102490355B1 (en) | Composition for preventing, improving or treating obesity comprising bile extract with increased taurochenodeoxycholic acid as an active ingredient and method for preparing the same | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR101293032B1 (en) | Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component | |
| CN102370145A (en) | Automatic nerve regulating agent with asparagus leaf as effective ingredient | |
| KR102034314B1 (en) | Composition for preventing, improving or treating muscular disease comprising Red Paprika extract or Capsanthin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |